Monday, August 10, 2026 · Covering: Fri–Mon
TL;DR
Markets closed the week higher after a soft July jobs report — the U.S. lost 23,000 jobs versus an expected +83,000 — sent bond yields down and pushed rate-cut odds sharply up, cheapening the debt that funds deals. That financing tailwind is showing up at scale: EA's record $55B take-private closed (the largest LBO ever), exchange operator ICE agreed to buy bond-trading platform MarketAxess for ~$6B, and Supernus and Indivior struck a ~$3.4B all-stock merger of equals in CNS biopharma. For recruiting, this weekend gives you three distinct deal archetypes to speak to — a sponsor megabuyout, a strategic platform bolt-on, and a merger of equals.
TOP 3 DEALS
DEAL 01 · LEVERAGED FINANCE / TMT
Leveraged Buyout
VALUE~$55B EV ($210/share)
STRUCTURE~$36B equity + ~$20B debt
BUYER ADVISORSJ.P. Morgan (lead debt arranger)
SELLER ADVISORSLionTree, Goldman Sachs (EA)
A consortium of Saudi Arabia's Public Investment Fund, private equity firm Silver Lake, and Jared Kushner's Affinity Partners completed its buyout of the maker of Madden, EA Sports FC and Battlefield, taking it private and off the public market. PIF supplied most of the roughly $36B equity check while J.P. Morgan arranged more than $20B of debt — lifting EA's borrowings from about $2.2B to $20B.
Why it matters for recruiting: This is the textbook "megabuyout is back" story. Be ready to explain how an LBO works in plain terms (buy a company mostly with borrowed money, use the target's own cash flow to service it), why $20B of new debt pressures margins and headcount, and why sponsors will pay up for durable, cash-generative IP. It also touches CFIUS/foreign-investment review — a clean way to show you understand deal risk beyond price.
DEAL 02 · FINANCIALS / FINTECH
Strategic M&A
VALUE~$6B ($167/share, all-cash)
RATIONALEPush into fixed-income trading
BUYER ADVISORSBofA Securities (ICE)
SELLER ADVISORSJ.P. Morgan (MarketAxess)
Intercontinental Exchange — owner of the NYSE — agreed to buy MarketAxess, the leading electronic marketplace for trading corporate bonds, to bolt institutional fixed-income execution onto its data-and-exchange empire. The deal deepens ICE's move from equities and data toward the larger, historically more manual bond market, where electronic trading is still gaining share.
Why it matters for recruiting: A strategic (not sponsor) deal driven by a clear synergy thesis: ICE monetizes MarketAxess's trading flow through its data and clearing rails. Great for discussing the difference between financial buyers (return on invested capital, leverage) and strategic buyers (revenue/cost synergies, platform expansion) — and why exchanges keep consolidating into "financial infrastructure" toll roads.
DEAL 03 · HEALTHCARE / BIOPHARMA
Merger of Equals
VALUE~$3.4B combined (all-stock)
OWNERSHIP / SYNERGIESIndivior 56.5% / Supernus 43.5%; ~$125M cost synergies
SUPERNUS ADVISORSCantor Fitzgerald (lead), Wells Fargo
INDIVIOR ADVISORSJefferies, Piper Sandler
Supernus and Indivior agreed to combine in an all-stock "merger of equals," creating a diversified central-nervous-system (CNS) biopharma company treating conditions like ADHD, depression and opioid addiction. Because it's stock-for-stock, no cash changes hands — the two shareholder bases simply combine, with Indivior holders ending up with the larger slice and roughly $125M of annual cost savings targeted.
Why it matters for recruiting: A merger of equals is worth knowing as a distinct archetype from a take-private or a strategic cash buy. Be ready to explain why companies use stock (preserves cash, shares risk, signals a partnership rather than a takeover), how the exchange ratio sets ownership split, and why "cost synergies" are the headline value driver in slower-growth pharma combinations.
SECTOR SIGNAL
DEFENSE / AEROSPACE
A&D dealmaking is running at record pace — 2025 announcements and deal value rose ~60% year-on-year — as European rearmament and supply-chain scarcity turn Tier 2/3 suppliers into prize targets for vertical integration and PE roll-ups. Source ↗
TECH / TMT
Tech M&A hit ~$472B in the first five months of 2026, up 48% y/y — but volume is down ~9%: capital is concentrating into a few giant AI-infrastructure megadeals rather than spreading across many mid-caps. Source ↗
INDUSTRIALS
TransDigm continues its bolt-on machine, agreeing to buy Prince & Izant from Industrial Growth Partners for ~$1.07B — a reminder that aerospace-components roll-ups remain a steady A&D deal engine. Source ↗
HEALTHCARE / OTHER
The Supernus–Indivior tie-up caps a busy stretch of pharma consolidation, with buyers seeking scale and cost synergies in defensive, cash-generative therapeutic niches. Source ↗
M&A / LEVERAGED FINANCE
EA's $55B close is being read as proof the megabuyout market has reopened: falling financing costs, resilient equity markets and a friendlier regulatory posture are emboldening sponsors to write ever-larger equity checks and syndicate $20B+ debt packages. Watch whether this "comeback of massive LBOs" pulls more take-privates out of the pipeline this fall. Source ↗
MARKET TONE
Jobs shock. The U.S. lost 23,000 jobs in July versus an expected +83,000; unemployment held at 4.1%. A clear signal the labor market is cooling faster than forecast. Source ↗
Stocks up on bad news. Equities rallied into the weekend as the soft print convinced traders the Fed won't need to stay restrictive — "bad news is good news" for rate-sensitive assets. Source ↗
Yields fall. Bond yields dropped as the market priced in higher odds of near-term rate cuts — directly lowering the cost of the debt that funds LBOs. Source ↗
Financing tailwind. Cheaper-money expectations plus measured inflation are compressing LBO financing costs — 2026 senior debt is pricing around SOFR + 450–650 bps — giving sponsors more certainty to commit. Source ↗
Deal machine re-engaging. A record LBO close, a strategic exchange tie-up, and a biopharma merger of equals over one stretch point to a broad reopening across financial buyers and strategics. Source ↗
INTERVIEW ANGLE
TOPIC: THREE WAYS TO BUY A COMPANY — AND WHEN EACH IS USED
This weekend handed you one of each major deal structure. If an interviewer asks you to compare them, use these three deals as your examples:
Sponsor LBO (EA). A private equity buyer uses mostly borrowed money to take a company private, betting the target's cash flow can service the debt and generate an equity return on exit. Cash to shareholders, company leaves the public market.
Strategic cash acquisition (ICE / MarketAxess). An operating company buys another with cash to capture synergies — here, running bond-trading flow through ICE's existing data and clearing infrastructure. Value comes from the two businesses being worth more together.
Merger of equals (Supernus / Indivior). Two similar-sized companies combine using stock, not cash — preserving liquidity, sharing risk, and splitting ownership by an exchange ratio. Cost synergies, not a control premium, are the headline.
How to bring it up: "Just this weekend you could see all three buyer playbooks — EA was a sponsor LBO, ICE/MarketAxess was a strategic cash deal for synergies, and Supernus/Indivior was an all-stock merger of equals. The common thread is that the soft jobs report pushed rate-cut odds up and financing costs down, which makes every one of those structures easier to get done."